Metronidazole fenbufen capsules

Metronidazole in this product has a strong antibacterial effect on most anaerobic bacteria, but has no effect on aerobic bacteria and facultative anaerobes. The antibacterial spectrum includes Bacteroides fragilis and other Bacteroides, Fusobacterium, Clostridium perfringens, Eubacterium, Veillonella, Peptococcus and Peptostreptococcus, etc. Its bactericidal concentration is slightly higher than the inhibitory concentration. The bactericidal mechanism of metronidazole has not been fully elucidated. The nitroreductase of anaerobic bacteria plays an important role in the energy metabolism of sensitive strains. The nitro group of this product is reduced to a cytotoxin, which acts on the DNA metabolism process of bacteria and promotes cell death. Resistant bacteria often lack nitroreductase and are therefore resistant to metronidazole. Fenbufen is a long-acting non-steroidal anti-inflammatory analgesic. After entering the body, it is metabolized into diphenyl ethyl ester, which can inhibit the activity of cyclooxygenase, reduce the synthesis of prostaglandins, and produce anti-inflammatory, analgesic and antipyretic effects.

This product is a compound preparation, and its components are: each tablet contains 100 mg of metronidazole and 75 mg of fenbufen.

This product is a capsule, and the contents are white or slightly yellow powder.

It is used for gingivitis, periodontitis and other diseases. It also has a certain effect on stomatitis (stomatitis is ulcers in the cheeks, tongue edges, upper palate, gums, etc., with redness, swelling and pain around the ulcers, and erosion on the ulcer surface. Traditional Chinese medicine believes that it is caused by heat accumulation in the spleen and stomach, inflammation of the heart fire, and floating of virtual fire.), glossitis, etc.

Oral. Adults: 2 capsules at a time, 3 times a day. The total amount per day should not exceed 14 capsules.

1. The most serious adverse reactions of this product are epileptic seizures and peripheral neuropathy at high doses, the latter of which is mainly manifested as numbness and paresthesia of the extremities. In some cases, long-term use of the drug may cause persistent peripheral neuropathy. 2. Other common adverse reactions: (1) Gastrointestinal reactions, such as stomach pain, burning sensation, nausea, loss of appetite, vomiting, diarrhea, abdominal discomfort, taste changes, dry mouth, metallic taste in the mouth, etc. A few serious adverse reactions include gastric ulcers, bleeding, and even perforation. (2) Reversible neutropenia. (3) Allergic reactions, rashes, hives, itching, etc. (4) Central nervous system symptoms, such as headache, dizziness, syncope, paresthesia, numbness of the extremities, ataxia and mental confusion. (5) Other symptoms include fever, vaginal candidiasis, cystitis, dysuria, dark urine color, etc., which are all reversible and recover on their own after stopping the drug. (6) Slight decrease in white blood cell count and slight increase in serum transferase are less common.

1. Patients with a history of allergy to this product or azole drugs are prohibited from using this product. 2. Patients with aspirin-induced asthma are prohibited from using this product. 3. Patients with active central nervous system diseases are prohibited from using this product. 4. Patients with blood diseases and peptic ulcers are prohibited from using this product. 5. Patients with severe liver and kidney damage are prohibited from using this product. 6. Pregnant and lactating women are prohibited from using this product. 7. Children are prohibited from using this product.

Precautions for children: Children are prohibited from using this product. Precautions for pregnancy and lactation: Precautions for pregnant and lactating women. This product can pass through the placenta and quickly enter the fetal circulation. Animal experiments have found that intraperitoneal administration is toxic to the fetus, while oral administration is non-toxic. There is no sufficient and strict control observation on the effect of this product on the fetus, so it is prohibited for pregnant women. The concentration of metronidazole in breast milk is similar to that in blood. Animal experiments have shown that metronidazole is carcinogenic to young mice, so it is not suitable for lactating women. If the drug must be used, breastfeeding should be suspended, and breastfeeding can be resumed 24 to 48 hours after the end of the treatment course. Precautions for the elderly: Elderly patients need to monitor blood drug concentrations and pay attention to renal toxicity when using this product due to decreased liver and kidney function.

1. This product can inhibit the metabolism of warfarin and other oral anticoagulants, enhance their effects, and cause the prothrombin time to be prolonged. 2. When used in combination with drugs that induce liver microsomal enzymes, such as phenytoin sodium and phenobarbital, it can enhance the metabolism of this product, reduce the blood drug concentration, and slow down the excretion of phenytoin sodium. 3. When used in combination with drugs that inhibit the activity of liver microsomal enzymes, such as cimetidine, it can slow down the metabolism and excretion of this product in the liver, prolong the blood elimination half-life (t1/2β) of this product, and the dosage should be adjusted according to the results of blood drug concentration determination. 4. This product interferes with the metabolism of disulfiram. When the two are used together, patients may experience mental symptoms after drinking. Therefore, those who have used disulfiram within two weeks should not use this product again. 5. This product interferes with the results of serum aminotransferase and lactate dehydrogenase determinations, and can reduce cholesterol and triglyceride levels.

Keep away from light and store in sealed container.

Each capsule contains metronidazole 0.1g, fenbufen 75mg

24 months.

Lepu Hengjiuyuan Pharmaceutical Co., Ltd.

• Founded in:

  2002-06-20

• Address:

  East of Qingnian Road, South of Bridge No. 21, Xinzheng Highway, Xinxiang County

• Tax NO.:

  91410700742508620M

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view